The CMS4 subtype is an interesting therapeutic target, TGFβ signalling inhibitors and targeted immunotherapies have been trialled with success in pre-clinical models to block cross talk between the tumour microenvironment and halt disease progression of stromal rich CMS4 CRC65,66. Here, TGFB1 is linked to neoplasm.